Incyte

Incyte to Test Its Cancer Drug Jakafi as a Treatment for COVID-19
Incyte to Test Its Cancer Drug Jakafi as a Treatment for COVID-19
Motley Fool
cancer
COVID-19
Incyte
Jakafi
Flag link:
Lilly, Incyte get FDA breakthrough therapy status for baricitinib to treat alopecia areata
Lilly, Incyte get FDA breakthrough therapy status for baricitinib to treat alopecia areata
Pharmaceutical Business Review
Eli Lilly
Incyte
breakthrough therapy
FDA
baricitinib
alopecia areata
Flag link:
Incyte hits endpoint in 2nd pivotal atopic dermatitis trial
Incyte hits endpoint in 2nd pivotal atopic dermatitis trial
Fierce Biotech
Incyte
ruxolitinib
clinical trials
atopic dermatitis
Flag link:
Can Jakafi hit $3B? Incyte thinks so—and it's got other launches on the way
Can Jakafi hit $3B? Incyte thinks so—and it's got other launches on the way
Fierce Pharma
Incyte
Jakafi
pemigatinib
Flag link:
Incyte Earnings, Revenue Beat in Q4
Incyte Earnings, Revenue Beat in Q4
Yahoo/Investing.com
Incyte
earnings
Flag link:
Eli Lilly and Incyte Record Another Positive Clinical Trial for Olumiant Works in Eczema
Eli Lilly and Incyte Record Another Positive Clinical Trial for Olumiant Works in Eczema
Motley Fool
Eli Lilly
Incyte
olumiant
eczema
clinical trials
atopic dermatitis
Flag link:
Novartis nabs priority review for a blockbuster-to-be aimed at NSCLC niche — delighting Incyte execs
Novartis nabs priority review for a blockbuster-to-be aimed at NSCLC niche — delighting Incyte execs
Endpoints
Incyte
Novartis
FDA
capmatinib
prioirty review
non-small cell lung cancer
Flag link:
Incyte's skin disease drug meets main goal in late-stage study
Incyte's skin disease drug meets main goal in late-stage study
Yahoo/Reuters
Incyte
clinical trials
atopic dermatitis
ruxolitinib
Flag link:
Incyte Commits $900M to MorphoSys for Rights to Lymphoma Drug
Incyte Commits $900M to MorphoSys for Rights to Lymphoma Drug
Xconomy
Incyte
MorphoSys
lymphoma
tafasitamab
Flag link:
Incyte stock slammed after study fails to hit goal
Incyte stock slammed after study fails to hit goal
Marketwatch
Incyte
clinical trials
itacitinib
graft vs host disease
Flag link:
Is IBD 50 Drugmaker Incyte Stock On The Cusp Of Innovation-Fueled Growth Spurt?
Is IBD 50 Drugmaker Incyte Stock On The Cusp Of Innovation-Fueled Growth Spurt?
Investors Business Daily
Incyte
Jakafi
innovation
Flag link:
FDA accepts Incyte’s NDA for priority review of pemigatinib to treat cholangiocarcinoma
FDA accepts Incyte’s NDA for priority review of pemigatinib to treat cholangiocarcinoma
Pharmaceutical Business Review
FDA
Incyte
priority review
pemigatinib
cholangiocarcinoma
Flag link:
Biopharma Q3: Pfizer, Merck, Amgen, Incyte and J&J
Biopharma Q3: Pfizer, Merck, Amgen, Incyte and J&J
BioSpace
earnings
Pfizer
Merck
Amgen
Incyte
JNJ
Flag link:
Why the Earnings Surprise Streak Could Continue for Incyte (INCY)
Why the Earnings Surprise Streak Could Continue for Incyte (INCY)
Yahoo/Zacks.com
Incyte
earnings
Flag link:
Incyte's cash cow Jakafi chugs along with positive frontline results for GVHD
Incyte's cash cow Jakafi chugs along with positive frontline results for GVHD
Endpoints
Incyte
FDA
graft vs host disease
Jakafi
Flag link:
3 Drug Stocks Poised for Gains After Cancer Conference
3 Drug Stocks Poised for Gains After Cancer Conference
Investopedia
ESMO
cancer
Amgen
Incyte
Bristol-Myers Squibb
Flag link:
ICER pulls report blasting ‘marginal’ RA drugs, citing need to rethink its approach
ICER pulls report blasting ‘marginal’ RA drugs, citing need to rethink its approach
Fierce Pharma
ICER
JAK inhibitors
rheumatoid arthritis
AbbVie
Rinvoq
Pfizer
Xeljanz
Incyte
olumiant
Flag link:
Incyte announces first patient treated in phase 3 trial program evaluating Ruxolitinib cream in patients with vitiligo
Incyte announces first patient treated in phase 3 trial program evaluating Ruxolitinib cream in patients with vitiligo
Pharmaceutical Business Review
Incyte
clinical trials
ruxolitinib
vitiligo
Flag link:
The Week Ahead In Biotech: Spotlight On ESMO Conference
The Week Ahead In Biotech: Spotlight On ESMO Conference
Yahoo/Benzinga
JNJ
daratumumab
Urogen
Rhythm Pharmaceuticals
Anavex
Aravive Biologics
TrovaGene
Incyte
AstraZeneca
Roche
Amgen
Aslan
G1 Therapeutics
GSK
Calithera Biosciences
Seattle Genetics
Immunomedics
Checkpoint Therapeutics
Aileron Therapeutics
Genocea Biosciences
AbbVie
Zymeworks
Flag link:
This Could Be a Big Year for Incyte
This Could Be a Big Year for Incyte
Motley Fool
Incyte
Jakafi
blood cancers
Flag link:

Pages